Can we predict who will respond to melanoma immunotherapy?

NCT ID NCT07407166

Recruiting now Knowledge-focused Sponsor: Institute of Oncology Ljubljana Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking 40 people in Slovenia with metastatic melanoma who are receiving standard first-line immunotherapy. Researchers want to see how well the treatment works and look for clues in blood, stool, and tumor samples that might predict who will benefit most. The goal is to improve personalized treatment for advanced melanoma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Immunotherapy (immune checkpoint inhibitors, such as anti-PD-1 with or without anti-CTLA-4)
What this could lead to: If successful, this could help doctors better predict which patients with metastatic melanoma will benefit from immunotherapy, leading to more personalized treatment plans.
What could go wrong: This is an observational study with only 40 participants, so results may not apply to everyone. It is not testing a new treatment, just gathering data on standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA METASTATIC MELANOMA

Contacts and locations

Locations

Institute of Oncology Ljubljana
RECRUITING

Ljubljana, 1000, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.